FDA-USPTO collaboration initiatives should be evidence-based, prioritize innovation
PhRMA
MARCH 1, 2023
The United States Patent and Trademark Office (USPTO) and the U.S. Food and Drug Administration (FDA) are in the process of considering new collaboration initiatives aimed at biopharmaceutical patents. As outlined in a recent public statement and written comments , PhRMA appreciates the agencies seeking public participation on important innovation policy issues and we strongly support the agencies stated commitment to “ensuring our innovation system strikes the appropriate balance—encouraging me
Let's personalize your content